Medical Director Articles

The term "article" is used to describe any bulletin article, web site article, educational handout or any other non-LCD document intended for public release that contains coverage/coding statements or medical review related billing or claims considerations.

Articles address local coverage, coding or medical review related billing and claims considerations, and may include any newly developed educational materials, coding instructions or clarification of existing medical review related billing or claims policy.

The article listing will continue to expand as additions are made.

Last Updated Jan 30 , 2024
Articles Source Posted
Billing and Coding: MolDX: ApoE Genotype (A55095 ) - R4 - Effective April 3, 2024 Apr 11, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58726) - R17 - Effective February 29, 2024 Apr 11, 2024
Trigger Point Injections (TPI) (L36859) - R5 and Billing and Coding: Trigger Point Injections (TPI) (A57702) - R4 - Effective April 1, 2024 Apr 11, 2024
Billing and Coding: MolDX: Proteomics Testing (A59642) - R3 - Effective April 1, 2024 Apr 11, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57332) - R11 - Effective April 1, 2024 Apr 11, 2024
Additional 2024 CPT/HCPCS Local Coverage Article (LCA) Update Apr 04, 2024
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55323) - R17 - Effective April 1, 2024 Apr 04, 2024
Self-Administered Drug Exclusion List (A53033) - R36 - Effective April 1, 2024 Apr 04, 2024
Billing and Coding: MolDX: Short Tandem Repeat (STR) Markers and Chimerism (CPT® codes 81265-81268) (A57843) - R3 - Effective April 4, 2024 Apr 04, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57527) - R18 - Effective April 01, 2024 Apr 04, 2024
Micro-Invasive Glaucoma Surgery (MIGS) Final LCD - Effective March 23, 2020 Apr 01, 2024
MolDX: Biomarkers in Cardiovascular Risk Assessment (L36362) - R9 - Effective March 21, 2024 Mar 28, 2024
MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (L38125) - R2 - Effective March 28, 2024 Mar 28, 2024
Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) - Published for Review and Comments Mar 28, 2024
Open Meeting Announcement Minimally Invasive Arthrodesis of the Sacroiliac Joint (SIJ) - April 18, 2024 Mar 28, 2024
2024 CPT/HCPCS Local Coverage Article (LCA) Updates Mar 28, 2024
Billing and Coding: MolDX: Molecular Biomarkers to Risk-Stratify Patients at Increased Risk for Prostate Cancer (A58724 ) - R3 - Effective March 12, 2024 Mar 21, 2024
Billing and Coding: MolDX: Targeted and Comprehensive Genomic Profile Next-Generation Sequencing Testing in Cancer (A56518) - R8 - Effective March 21, 2024 Mar 21, 2024
Billing and Coding: MolDX: Proteomics Testing (A59642) - R2 - Effective January 31, 2024 Mar 14, 2024
MolDX: NRAS Genetic Testing (L36339) - R7 - Effective July 27, 2023 Mar 14, 2024
Multi-Jurisdictional CAC Meeting Announcement - MolDX: Biomarker Risk Stratification Testing in DCIS - April 22, 2024, 2 p.m. to 4 p.m. ET Mar 11, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58726) - R16 - Effective April 17, 2022 Mar 07, 2024
MolDX: Defining panel services in MolDX (A59687) - Effective February 29, 2024 Feb 29, 2024
Billing and Coding: MolDX: Molecular Testing for Solid Organ Allograft Rejection (A58170) - R6 - Effective February 29, 2024 Feb 29, 2024
MolDX: Prometheus® IBD sgi Diagnostic® Policy (L37313) - R7 - Effective February 29, 2024 Feb 29, 2024
Billing and Coding: MolDX: Proteomics Testing (A59642) - R1 - Effective January 31, 2024 Feb 22, 2024
Local Coverage Determination (LCD) Finalized - Effective April 1, 2024 Feb 15, 2024
Billing and Coding: FDA Approved CLL Companion Diagnostic Test (A56013) Retirement - Effective March 30, 2023 Feb 08, 2024
Billing and Coding: MolDX: Genetic Testing for BCR-ABL Negative Myeloproliferative Disease (A57422) - R10 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: MolDX: Microsatellite Instability-High (MSI-H) and Mismatch Repair Deficient (dMMR) Biomarker for Patients with Unresectable or Metastatic Solid Tumors (A56104) - R5 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: Minimal Residual Disease Testing for Hematologic Cancers (A58997) - R5 - Effective January 1, 2024 Feb 01, 2024
Billing and Coding: MolDX: DecisionDX-Melanoma (A57418) Retirement - Effective August 8, 2022 Jan 25, 2024
Sacroiliac Joint Injections and Procedures (A59246) - R4 - Effective January 25, 2024 Jan 25, 2024
Billing and Coding: MolDX: Pharmacogenomics Testing (A57385) - R13 - Effective January 25, 2024 Jan 25, 2024
Billing and Coding: MolDX: Plasma-Based Genomic Profiling in Solid Tumors (A58975) - R4 - Effective January 1, 2024 Jan 25, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57527) - R17 - Effective January 1, 2024 Jan 25, 2024
Proposed Local Coverage Determinations - Published for Review and Comments Jan 18, 2024
Billing and Coding: MolDX: Next-Generation Sequencing for Solid Tumors (A57905) - R6 - Effective January 1, 2024 Jan 18, 2024
Billing and Coding: MolDX: Next-Generation Sequencing Lab-Developed Tests for Myeloid Malignancies and Suspected Myeloid Malignancies (A57892) - R7 - Effective January 1, 2024 Jan 18, 2024
Billing and Coding: MolDX: Prognostic and Predictive Molecular Classifiers for Bladder Cancer (A58187) - R7 - Effective January 1, 2024 Jan 18, 2024
Local Coverage Determinations (LCDs) Finalized - Effective February 25, 2024 Jan 15, 2024
Billing and Coding: MolDX: Minimal Residual Disease Testing for Solid Tumor Cancers (A58456) - R6- January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Molecular Diagnostic Tests (MDT) (A57527) - R16- January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Repeat Germline Testing (A57332) - R10 - January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Molecular Syndromic Panels for Infectious Disease Pathogen Identification Testing (A58726) - R15 - January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Fragile X (A55242) - R6 - January 1, 2024 Jan 11, 2024
Billing and Coding: MolDX: Proteomics Testing (A59642) - Effective January 31, 2024 Jan 04, 2024
Billing and Coding: Implantable Infusion Pumps for Chronic Pain (A55323) - R16 - Effective January 1, 2024 Jan 04, 2024
2024 CPT/HCPCS Local Coverage Article (LCA) Updates Dec 28, 2023
Micro-Invasive Glaucoma Surgery (MIGS) Dec 28, 2023